Mediators of Inflammation / 2013 / Article / Tab 1

Research Article

Impact of Temporomandibular Joint Pain in Rheumatoid Arthritis

Table 1

Demographic and background data for 33 patients with temporomandibular joint (TMJ) involvement of rheumatoid arthritis.

MedianPercentile% abnn
25th75th

Age Years47415433
GenderF/M29/4
Duration
 General diseaseYears651133
 TMJ symptomsYears21433
SmokingYes/no5/28
Systemic disease activity
 Disease activity score (28)0–103.93.54.932
 Number of painful regions0–21981233
 Erythrocyte sedimentation ratemm/hr4028708533
 C-reactive proteinmg/L86115326
 Rheumatoid factorIU/mL2725348426
 ACPA4226
 Thrombocyte particle count109/L306246342933
Medication
 NSAID%94
 DMARD%100
 Glucocorticoid%3
 Anti-TNF%46

% abn: percentage of observations with positive or abnormal values (when applicable), n: number of observations, M: males, F: females, IU: international units, NSAID: nonsteroidal anti-inflammatory drug, DMARD: disease-modifying antirheumatic drug, anti-TNF: biologic drug specifically targeting tumor necrosis factor. The following values were considered abnormal: rheumatoid factor >14 IU, C-reactive protein >4 mg/L, erythrocyte sedimentation rate >20 mm/h, thrombocyte particle count >300 × 109/L, and ACPA >5 U/mL. The disease activity score for 28 joints was assessed at the time of clinical examination.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.